Paul S. Danielian

Paul S. Danielian

Auto-generated profile, based on publicly available information

Paul S. Danielian

David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 1998 in Current Biology
Verified
Journal Article
Closed access
PDPaul S. Danielian
Paul S. Danielian
DMDavid Muccino
David Muccino
DRDavid H. Rowitch
David H. Rowitch
SMSimon K. Michael
Simon K. Michael
AMAndrew P. McMahon
Andrew P. McMahon

1 September 1998 in Current Biology
Verified
Journal Article
Closed access
BSB. St-Jacques
B. St-Jacques
HDH.R. Dassule
H.R. Dassule
IKI. Karavanova
I. Karavanova
VBV.A. Botchkarev
V.A. Botchkarev
JLJ. Li
J. Li
AMA.P. McMahon
A.P. McMahon

25 May 1995 in Nucleic Acids Research
Verified
Journal Article
Closed access
PDF file
TLTrevor D. Littlewood
Trevor D. Littlewood
DHDavid C. Hancock
David C. Hancock
PDPaul S. Danielian
Paul S. Danielian
MPMalcolm G. Parker
Malcolm G. Parker
GEGerard I. Evan
Gerard I. Evan
A number of proteins have been rendered functionally oestrogen-dependent by fusion with the hormone-binding domain of the oestrogen receptor. There are, however, several significant disadvantages with such fusion proteins. First, their use In cells in vitro requires phenol red-free medium and laborious stripping of steroid hormones from serum In order to avoid constitutive activation. Secondly, control of oestrogen receptor fusion proteins In vivo is precluded by high endogenous levels of circulating oestrogens. Thirdly, the hormone-binding domain of the oestrogen receptor functions as a hormone-dependent transcriptional activation domain making interpretation of fusions with transcription factors problematical. In order to overcome these drawbacks we have used a transcrip-tlonally inactive mutant of the murine oestrogen receptor which is unable to bind oestrogen yet retains normal affinity for the synthetic ligand, 4-hydroxyta-moxifen. When the hormone-binding domain of this mutant oestrogen receptor is fused to the C-terminus of the c-Myc protein, Myc-induced proliferation and apoptosis In fibroblasts becomes dependent on 4-hydroxytamoxifen, but remains refractory to 17β-oestradlol.

1 May 1992 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SDS Dauvois
S Dauvois
PDP S Danielian
P S Danielian
RWR White
R White
MPM G Parker
M G Parker
The ability of estrogens to stimulate the transcriptional activity of the estrogen receptor can be inhibited by a diverse range of estrogen antagonists. Here we show that the antiestrogen ICI 164,384, N-(n-butyl)-11-[3,17 beta-dihydroxy-estra-1,3,5(10)-trien-7 alpha-yl]N-methylundecanamide, rapidly reduces the levels of receptor protein transiently expressed in cells without affecting receptor mRNA abundance. The reduction in the levels of receptor protein is dose dependent, reversible by estradiol, and mediated by the hormone-binding domain of the receptor. Pulse-chase experiments indicate that the half-life of the receptor is reduced from approximately 5 hr in the presence of estradiol to less than 1 hr by ICI 164,384. A similar reduction in estrogen receptor levels is demonstrated in human breast cancer cells treated with ICI 164,384. We discuss the possibility that the increased turnover of the receptor might be a consequence of impaired receptor dimerization.

4 August 2010 in Nature
Verified
Journal Article
Open access
PDF file
ECEliezer Calo
Eliezer Calo
JQJose A. Quintero-Estades
Jose A. Quintero-Estades
PDPaul S. Danielian
Paul S. Danielian
SNSimona Nedelcu
Simona Nedelcu
SBSeth D. Berman
Seth D. Berman
JLJacqueline A. Lees
Jacqueline A. Lees
The tumour suppressor Rb (retinoblastoma protein) is mutated in about one-third of human tumours. It suppresses the activity of certain transcription factors and potentiates the activity of others, and has been shown to affect the differentiation of different cell lineages in vitro. Jacqueline Lees and colleagues now show that Rb plays a role in determining fate choice between bone cell and brown adipose tissue formation in vivo in mouse osteosarcoma models, acting via the bone and fat master regulators Runx2 and PPARγ The retinoblastoma tumour suppressor protein pRb can suppress the activity of certain transcription factors and potentiate the activity of others, and has been shown to affect the differentiation of different cell lineages in vitro. These authors show that the Rb gene has a role in driving bone cell formation or brown adipose tissue formation in vivo. Mutation of the retinoblastoma gene (RB1) tumour suppressor occurs in one-third of all human tumours and is particularly associated with retinoblastoma and osteosarcoma1. Numerous functions have been ascribed to the product of the human RB1 gene, the retinoblastoma protein (pRb). The best known is pRb’s ability to promote cell-cycle exit through inhibition of the E2F transcription factors and the transcriptional repression of genes encoding cell-cycle regulators1. In addition, pRb has been shown in vitro to regulate several transcription factors that are master differentiation inducers2. Depending on the differentiation factor and cellular context, pRb can either suppress or promote their transcriptional activity. For example, pRb binds to Runx2 and potentiates its ability to promote osteogenic differentiation in vitro3. In contrast, pRb acts with E2F to suppress peroxisome proliferator-activated receptor γ subunit (PPAR-γ), the master activator of adipogenesis4,5. Because osteoblasts and adipocytes can both arise from mesenchymal stem cells, these observations suggest that pRb might play a role in the choice between these two fates. However, so far, there is no evidence for this in vivo. Here we use mouse models to address this hypothesis in mesenchymal tissue development and tumorigenesis. Our data show that Rb status plays a key role in establishing fate choice between bone and brown adipose tissue in vivo.

11 October 1994 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
VCVincent Cavailles
Vincent Cavailles
SDS Dauvois
S Dauvois
PDP S Danielian
P S Danielian
MPM G Parker
M G Parker
The ligand binding domain of the estrogen receptor contains a hormone-dependent transcriptional activation function. To investigate the mechanism by which it stimulates transcription, we have expressed fusion proteins containing either the wild-type or a transcriptionally defective form of this domain fused to glutathione-S-transferase and searched for proteins that specifically interact in vitro. By far-Western blotting, three proteins of 160, 140, and 80 kDa expressed in different mammalian cells (HeLa, ZR75-1, and COS-1) were shown to associate directly with the wild-type receptor in the presence of estrogen. Two additional proteins appeared to interact indirectly with the hormone binding domain since they were detected only by a pull-down assay. All of these interactions were abolished by antiestrogens, such as 4-hydroxytamoxifen, ICI 164384, or ICI 182780, which inhibit hormone-dependent transcription. Moreover, they were not observed with the transcriptionally defective form of the receptor even in the presence of estrogen. Thus, since the ability of these proteins to interact with the hormone binding domain correlates with its transcriptional activity, one or more of them may contribute to hormone-dependent transcriptional activation by the estrogen receptor.